Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:clinicalTrialRegion |
gptkb:China
gptkb:United_States |
| gptkbp:developedBy |
Antengene Corporation
|
| gptkbp:firstClinicalTrial |
2021
|
| https://www.w3.org/2000/01/rdf-schema#label |
ATG-101
|
| gptkbp:indication |
gptkb:B-cell_non-Hodgkin_lymphoma
solid tumors |
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
PD-L1/4-1BB bispecific antibody
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:4-1BB
PD-L1 |
| gptkbp:bfsParent |
gptkb:Antengene
|
| gptkbp:bfsLayer |
7
|